Primaris REIT Provides HBC Exposure Update
TORONTO, March 10, 2025--(BUSINESS WIRE)--Primaris Real Estate Investment Trust ("Primaris" or the "Trust") (TSX: PMZ.UN) announces today its exposure to the Hudson's Bay Company ULC, the retailer Hudson's Bay and TheBay.com ("HBC"), in response to HBC's March 7, 2025, press release stating that it has commenced proceedings under the Companies' Creditors Arrangement Act.
Primaris has been preparing for this announcement for an extended period of time.
HBC Exposure
As at March 10, 2025, Primaris REIT's exposure to HBC is as follows:
10 HBC locations totaling 1,124,000 square feet of gross leasable area ("GLA");
12th largest tenant by annualized minimum rent;
Approximately $11.6 million total gross rental revenue, per annum;
$10.33 weighted average gross rent per occupied square foot;
Approximately $4.6 million net rental revenue per annum, or 1.4% of total annualized minimum rent;
$4.14 weighted average net rent per occupied square foot;
February rent was received for all locations excluding two centres; and
In addition to the 10 HBC locations in Primaris' portfolio, there is a shadow-anchor HBC located at Devonshire Mall in Windsor, Ontario which is owned by an unrelated HBC joint venture.
"Primaris REIT has been preparing for this day for a very, very long time, in fact years. We have learned so much over the past 10+ years with the departure of Zellers, Target, Sears, and now potentially HBC," said Patrick Sullivan, President and Chief Operating Officer. "Although there could be an impact to our financial and operating metrics in the short term, Primaris has detailed plans for all 10 locations, and is ready to take action if and when any locations are disclaimed."
The below table lists Primaris' properties with HBC tenancies.
As at March 10, 2025
(in '000s square feet, unless otherwise indicated)
(unaudited)
Property Ownership at Share
Property GLA
at Share
HBC GLA
at Share
Cataraqui Town Centre
945 Gardiners Rd, Kingston, ON
50 %
286.2
56.5
Conestoga Mall
550 King St N,
Waterloo, ON
100 %
666.1
130.6
Les Galeries de la Capitale
5401 Bd des Galeries, Québec, QC
100 %
987.5
163.3
Medicine Hat Mall
3292 Dunmore Road SE,
Medicine Hat, AB
100 %
467.5
93.2
Orchard Park Shopping Centre
2271 Harvey Avenue, Kelowna, BC
100 %
651.1
127.3
Oshawa Centre
419 King St W,
Oshawa, ON
100 %
1,215.2
122.6
Place d'Orleans Shopping Centre
110 Place d'Orleans Drive, Orleans, ON
50 %
350.1
57.8
Southgate Centre
5015 111 St NW, Edmonton, AB
50 %
425.4
118.3
St Albert Centre
375 St. Albert Trail,
St. Albert, AB
100 %
352.8
93.3
Sunridge Mall
2525 36th Street NE, Calgary, AB
100 %
803.7
161.3
10 locations
6,205.6
1,124.2
The below table illustrates the weighted average net rent and occupied GLA for Commercial Retail Unit ("CRU") and large format tenants for Primaris' portfolio at December 31, 2024. HBC's weighted average net rent per occupied square foot for the 10 locations is $4.14.
As at December 31, 2024
(per occupied square foot unless otherwise indicated) (unaudited)
Weighted Average
Net Rent1
Occupied GLA
('000s of square feet)
GLA Proportions
CRU tenants
$
43.26
5,204
42
%
Large format tenants
$
14.37
7,363
59
%
$
25.28
12,567
100
%
1 Supplementary financial measure, see Section 1, "Basis of Presentation" - "Use of Operating Metrics" of the December 31, 2024 Management's Discussion and Analysis.
The Primaris portfolio includes over 2,700 stores, of which there are approximately 35 co-tenancy clauses that name HBC. Co-tenancy clauses are provisions commonly found in commercial real estate leases that stipulate certain conditions under which a tenant's rent or other obligations may be reduced or modified. These clauses typically come into effect when specific anchor tenants, such as HBC, or a certain percentage of tenants within a shopping centre or retail complex cease operations or vacate their premises. These clauses may not be triggered simply by HBC closing. The purpose of a co-tenancy clauses is to protect tenants from potential loss of business and foot traffic due to the absence of prominent anchor tenants. Over the past number of decades, reference to anchor requirements and named tenants have been removed from tenants' leases due to the changing enclosed mall merchandise mix and the reliance on anchor tenants for foot traffic.
About Primaris Real Estate Investment Trust
Primaris is Canada's only enclosed shopping centre focused REIT, with ownership interests primarily in leading enclosed shopping centres located in growing Canadian markets. The portfolio totals 15.0 million square feet, valued at approximately $4.6 billion at Primaris' share. Economies of scale are achieved through its fully internal, vertically integrated, full-service national management platform. Primaris is very well-capitalized and is exceptionally well positioned to take advantage of market opportunities at an extraordinary moment in the evolution of the Canadian retail property landscape.
Forward-Looking Statements
Certain statements included in this news release constitute ''forward-looking information'' or "forward-looking statements" within the meaning of applicable securities laws. The words "will", "expects", "plans", "estimates", "intends" and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Specific forward-looking statements made or implied in this news release include but are not limited to statements regarding: Primaris' future results, performance, prospects and opportunities, including with respect to the impact of the closure of any Hudson Bay Company locations in the portfolio, the Trust's strategy and plans and the Trust's portfolio quality. Forward-looking statements are provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements are not guarantees of future performance and are based on estimates and assumptions that are inherently subject to risks and uncertainties. Primaris cautions that although it is believed that the assumptions are reasonable in the circumstances, actual results, performance or achievements of Primaris may differ materially from the expectations set out in the forward-looking statements. Material risk factors and assumptions include those set out in the Trust's management's discussion and analysis for the three months and years ended December 31, 2024 and 2023 ("MD&A") which is available on SEDAR+, and in Primaris' other materials filed with the Canadian securities regulatory authorities from time to time. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates. Other than as specifically required by law, Primaris undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
Non-GAAP Measures
The Trust's financial statements are prepared in accordance with IFRS accounting standards as issued by the IASB, however, in this news release, Primaris also uses a number of measures which do not have a standardized meaning prescribed under generally accepted accounting principles ("GAAP") in accordance with IFRS. These non-GAAP measures, which are denoted in this news release by the suffix "**" include non-GAAP financial measures and non-GAAP ratios, each as defined in National Instrument 52-112, Non-GAAP and Other Financial Measures Disclosure ("NI 52-112"). None of these non-GAAP measures should be construed as an alternative to financial measures calculated in accordance with GAAP. Furthermore, these non-GAAP measures may not be comparable to similar measures presented by other real estate entities and should not be construed as an alternative to financial measures determined in accordance with IFRS. Additional information regarding these non-GAAP measures, including definitions, an explanation of management's reasons as to why it believe the measure is useful to investor can be found in the section entitled :Non-GAAP Measures" in the MD&A. Reconciliations to the most directly comparable GAAP figure, where applicable, can be found in the Trust's MD&A, which is available on the Trust's profile on SEDAR+ at www.sedarplus.ca.
Use of Operating Metrics
Primaris uses certain operating metrics to monitor and measure the operational performance of its portfolio. Operating metrics in this news release include, amount others, in-place occupancy, weighted average gross rent per occupied square foot and weighted average net rent per occupied square foot. These operating metrics, which may constitute supplementary financial measures as defined in NI 52-112, are not derived from directly comparable measures contained in the Trust's financial statements but may be used by management and disclosed on a periodic basis to depict the historical or future expected operating performance of the Trust' portfolio. Weighted average gross rent per occupied square foot is defined as total annual gross rent divided by occupied GLA.
Primaris also uses certain nonfinancial operating metrics to describe its portfolio and portfolio operation performance. Non-financial operation metrics in this news release include, among others, gross leasable area ("GLA") and weighted average lease term. For greater certainty, the portfolio operating metrics in this news release include only the Trust's proportionate ownership of the 8 properties held in co-ownerships.
For more information: TSX: PMZ.UN www.primarisreit.com www.sedarplus.ca
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310598460/en/
Contacts
Alex AveryChief Executive Officer416-642-7837aavery@primarisreit.com
Rags DavloorChief Financial Officer416-645-3716rdavloor@primarisreit.com
Claire MahaneyVP, Investor Relations & ESG647-949-3093cmahaney@primarisreit.com
Timothy PireChair of the Boardchair@primarisreit.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the 'Court') has fully dismissed the application (CV-25-00743454-00CL) (the 'Application') issued by Apollo Technology Capital Corporation ('Apollo') and Nobul Technologies Inc. (together with Apollo, the 'Applicants') against the Company on May 16, 2025 (the 'Notice'). The Applicants sought an order from the Court, amongst other things, appointing a third-party independent chair to preside over the Annual and Special Meeting of Shareholders of the Company (the 'Meeting') on June 16, 2025. The Applicants argued that MediPharm has a 'design or plan to invalidate proxies' and that the Company had acted improperly warranting the appointment of a third-party independent chair. The Court dismissed the Application in full. In doing so, the Court found that a third-party independent chair was not required in the circumstances as there was no evidence or indication that MediPharm's proposed meeting chair will act unfairly at the Meeting. Regarding the conduct of Apollo's principal, Mr. Regan McGee, the Court found: 'The evidence shows that Mr. McGee has threatened to release a draft press release which, among other things, compared Mr. Pidduck to known serial killers. Press Releases have also been issued by Mr. McGee or the Applicants which accuse MediPharm and the Board of securities fraud, breach of fiduciary duty and running a corrupt election process to entrench themselves. Mr. McGee has threatened to sue the Board by way of a derivative action for breach of fiduciary duty and associated damages because of the rejection of the $3.4 million offer and has commenced a lawsuit against MediPharm, two of its senior officers and directors, as well as the Company's external litigation firm (Tyr LLP) and counsel (James Bunting) which claimed $50 million in damages. Mr. McGee, repeated the allegations set out in the lawsuit in the Dissident Circular and then abandoned and withdrew the claim against Tyr LLP and Mr. Bunting, and agreed to terms of settlement that included a declaration by Mr. McGee that Tyr LLP and Mr. Bunting are not in a conflict of interest in acting for MediPharm, that they had not misused confidential information, that Mr. McGee would not disparage Mr. Bunting or Tyr LLP and provided a full release to Tyr LLP and Mr. Bunting.' The Company remains committed to a fair shareholder meeting process, in compliance with its constating documents and all applicable laws. We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm's Board of Directors (the 'Board') and the other matters being considered at the Meeting. To ensure your proxy is counted at the Meeting, please submit it well in advance of the June 13 proxy cut-off. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@ American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, any impacts to MediPharm shareholders of the actions relating to the Applicants or Mr. McGee, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they in to access your portfolio

Yahoo
36 minutes ago
- Yahoo
Xtract One Technologies Inc. Announces $7 Million 'Bought Deal' Public Offering
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES BASE SHELF PROSPECTUS IS ACCESSIBLE AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE ON SEDAR+ WITHIN TWO BUSINESS DAYS TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- June 11, 2025 – Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, (the "Company" or "Xtract One") is pleased to announce that it has entered into an agreement with Ventum Capital Markets (the "Underwriter") pursuant to which the Underwriter has agreed to purchase 18,000,000 units (the "") from the treasury of the Company, at a price of $0.39 per Unit (the 'Issue Price') and offer them to the public by way of prospectus supplement for total gross proceeds of $7,020,000 (the "Offering"). Each Unit will consist of one common share of the Company (each a 'Common Share') and one common share purchase warrant (each full warrant, a 'Warrant' and collectively the 'Warrants'). The Company has granted the Underwriter an option to purchase up to an additional 15% of the Offered Securities at the Issue Price. The Over-Allotment Option may be exercised in whole or in part to purchase Offered Securities as determined by the Underwriter upon written notice to the Company at any time up to 30 days following the Closing Date (the 'Over-Allotment Option'). The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes. The Offered Securities will be offered (i) by way of a prospectus supplement to the base shelf prospectus of the Company dated February 6, 2024 (the 'Base Shelf Prospectus') to be filed in all provinces and territories of Canada, except Quebec (the 'Prospectus Supplement'); (ii) may be distributed in the United States to Qualified Institutional Buyers (as defined in Rule 144A under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act')) pursuant to an exemption under Rule 144A; and (iii) may be distributed outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company's securities under domestic or foreign securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The Offering is expected to close on or about June 18, 2025, or such other date as the Company and the Underwriter may agree, and is subject to customary closing conditions, including the approval of the securities regulatory authorities and the Toronto Stock Exchange. Access to the Prospectus Supplement, the Base Shelf Prospectus and any amendments thereto are provided in Canada in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus supplement and any amendment to such documents. The Base Shelf Prospectus is, and the Prospectus Supplement will be (within two business days from the date hereof), accessible through SEDAR+ at An electronic or paper copy of the Prospectus Supplement, the Base Shelf Prospectus and any amendment thereto may be obtained, without charge, from Ventum Financial Corp., or email at ecm@ by providing the contact with an email address or address, as applicable. About Xtract One Xtract One Technologies is a leading technology-driven provider of threat detection and security solutions leveraging AI to deliver seamless and secure experiences. The Company makes unobtrusive weapons and threat detection systems that are designed to assist facility operators in prioritizing- and delivering improved 'Walk-right-In' experiences while enhancing safety. Xtract One's innovative portfolio of AI-powered Gateway solutions excels at allowing facilities to discreetly screen and identify weapons and other threats at points of entry and exit without disrupting the flow of traffic. With solutions built to serve the unique market needs for schools, hospitals, arenas, stadiums, manufacturing, distribution, and other customers, Xtract One is recognized as a market leader delivering the highest security in combination with the best individual experience. For more information, visit or connect on Facebook, X, and LinkedIn. About Threat Detection Systems Xtract One solutions, when properly configured, deployed, and utilized, are designed to help enhance safety and reduce threats. Given the wide range of potential threats in today's world, no threat detection system is 100% effective. Xtract One solutions should be utilized as one element in a multilayered approach to physical security. For further information, please contact: Xtract One Inquiries: info@ Media Contact: Kristen Aikey, JMG Public Relations, 212-206-1645, kristen@ Investor Relations: Chris Witty, Darrow Associates, 646-438-9385, cwitty@ Forward-Looking InformationThis news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding the anticipated completion of the Offering, intended use of proceeds from the Offering, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking statements'. Forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not expect', 'is expected', 'estimates', 'intends', 'anticipates' or 'does not anticipate', 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company's limited operating history and lack of historical profits; risks related to the Company's business and financial position; fluctuations in the market price of the Company's Common Shares; that the Company may not be able to accurately predict its rate of growth and profitability; the failure of the Company and/or the Underwriter to satisfy closing conditions to the Offering; whether the Over-Allotment Option will be exercised; the failure of the Company to satisfy certain TSX additional listing requirements in respect of the Offered Securities; the failure of the Company to use any of the proceeds received from the Offering in a manner consistent with current expectations; reliance on management; the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, clients and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no intention to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason, except as required by law.

Yahoo
41 minutes ago
- Yahoo
Generation Mining Announces $10 Million Bought Deal Financing
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ TORONTO, June 11, 2025 /CNW/ - Generation Mining Ltd. (TSX: GENM) (OTCQB: GENMF) ("Generation Mining" or the "Company") announced today that it has entered into an agreement with Stifel Nicolaus Canada Inc. ("Stifel Canada") to act as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters (collectively, the "Underwriters") in connection with a "bought deal" private placement offering of 27,027,027 Units of the Company at a price of C$0.37 per Unit (the "Offering Price") for gross proceeds to the Company of up to C$10,000,000 (the "Offering"), with the Units to be issued pursuant to the Listed Issuer Financing Exemption (as defined below). Each Unit will consist of one common share in the capital of the Company and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to purchase one common share of the Company at a price of C$0.48 per common share at any time on or before that date which is 36 months after the date that is 61 days following the closing date of the Offering. The Company has granted to the Underwriters an option, exercisable up to 48 hours prior to the closing date, to purchase for resale up to an additional 15% of Units at the Offering Price for additional gross proceeds of up to C$1,500,000. The Company intends to use the net proceeds received from the Offering for development purposes at the Company's Marathon Project and general corporate purposes. The Offering is expected to close on or about June 24, 2025 and is subject to the Company receiving all necessary regulatory approvals, including the conditional approval from the Toronto Stock Exchange. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), the Units will be offered for sale to purchasers resident in Canada, except Quebec, and/or other qualifying jurisdictions pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"). As the Offering is being completed pursuant to the Listed Issuer Financing Exemption, the Units issued pursuant to the Offering will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document related to the Offering that can be accessed under the Company's issuer profile on SEDAR+ at and on the Company's website at Prospective investors should read the offering document before making an investment decision. No U.S. Offering or RegistrationThis news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. About the CompanyGeneration Mining's focus is the development of the Marathon Project, a large undeveloped copper-palladium deposit in Northwestern Ontario. The Marathon Property covers a land package of approximately 26,000 hectares, or 260 square kilometers. Gen Mining is dedicated to fostering a greener future by promoting sustainability, empowering communities, and delivering value to our stakeholders. The Feasibility Study (the "Technical Report") estimated a Net Present Value (using a 6% discount rate) of C$1.07 billion, an Internal Rate of Return of 28%, and a 1.9-year payback based on the 3-yr trailing average metal prices at the effective date of the Technical Report. Over the anticipated 13-year mine life, the Marathon Project is expected to produce 2,161,000 ounces of palladium, 532 million lbs of copper, 488,000 ounces of platinum, 160,000 ounces of gold and 3,051,000 ounces of silver in payable metals. For more information, please review the Feasibility Study filed under the Company's profile at or on the Company's website at Qualified PersonThe scientific and technical content of this news release has been reviewed and approved by Daniel Janusauskas, Technical Services Manager of Generation PGM Inc., a wholly-owned subsidiary of the Company, and a Qualified Person as defined by Canadian Securities Administrators National Instrument 43-101 Standards of Disclosure for Mineral Projects. Forward-Looking InformationThis news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to Offering, the proposed use of proceeds of the Offering, , receipt of all regulatory approvals related to the Offering, and the expected closing date of the Offering. Although the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include the timing of the Offering and regulatory approval of the Offering; timing for a construction decision; the progress of development at the Marathon Project, including progress of project expenditures and contracting processes, the Company's plans and expectations with respect to liquidity management, continued availability of capital and financing, the future prices of palladium, copper and other commodities, permitting timelines, exchange rates and currency fluctuations, increases in costs, requirements for additional capital, and the Company's decisions with respect to capital allocation, and the impact of COVID-19, inflation, global supply chain disruptions, global conflicts, including the wars in Ukraine and Israel, the project schedule for the Marathon Project, key inputs, staffing and contractors, continued availability of capital and financing, uncertainties involved in interpreting geological data and the accuracy of mineral reserve and resource estimates, environmental compliance and changes in environmental legislation and regulation, the Company's relationships with Indigenous communities, results from planned exploration and drilling activities, local access conditions for drilling, and general economic, market or business conditions, as well as those risk factors set out in the Company's annual information form for the year ended December 31, 2024, and in the continuous disclosure documents filed by the Company on SEDAR+ at Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR+ at SOURCE Generation Mining Ltd. View original content: